OBJECTIVETo determine whether B7-2 could improve hepatitis B virus (HBV)-specific immunity induced by inoculation of a plasmid encoding HBV preS2+S HBV DNA vaccine.

METHODSB7-2 expression plasmids were inoculated with the DNA vaccine in the gastrocemius muscles. Then the cytolytic T Lymphocyte activity (CTL), the delayed-type hypersensitivity (DTH) response and the titers of anti-HBs were analysed.

RESULTSThe DTH response and CTL activity were significantly enhanced when B7-2 expression plasmids were coinoculated with the DNA vaccine (P<0.01), but the titers of anti-HBs were unaffected (P>0.05).

CONCLUSIONSThe results suggest that B7-2 expression plasmid could improve HBV specific cell-mediated immunity induced by HBV DNA vaccine, and the gene-based coinoculation strategy using HBV viral antigen and B7-2 costimmulating could be a powerful means of combating HBV infection.

Adjuvants, Immunologic ; Animals ; Antigens, CD ; immunology ; B7-2 Antigen ; Hepatitis B Antibodies ; biosynthesis ; Hepatitis B Vaccines ; immunology ; Hypersensitivity, Delayed ; immunology ; Male ; Membrane Glycoproteins ; immunology ; Mice ; Mice, Inbred C57BL ; Plasmids ; T-Lymphocytes, Cytotoxic ; immunology ; Vaccines, DNA ; immunology

Objective: To analyze the efficacy of recombinant activated factor Ⅶ a (rF Ⅶ a) on hematonosis with moderate or severe bleeding signs. Methods: Of total 16 cases with rF Ⅶ a treatment from May 2013 to May 2016, 8 cases received allogeneic hematopoietic stem cells transplantation (allo-HSCT) and the other were non-transplantation patients. In two groups, there was no significant difference on rF Ⅶ a usage and dosage. 15 patients with acute graft-versus-host disease (aGVHD) after allo-HSCT were control group (without rF Ⅶ a) . Results: ①The total response rate was 75.0% (6/8) in non-transplantation group and 37.5% (3/8) in transplantation group, respectively. Median interval for hemorrhage stop was 38.5 hours in non-transplantation group and 63.0 hours in transplantation group. The median overall survival (OS) was 201.0 and 29.0 days for non-transplantation group and transplantation group, respectively, and the OS rate was 50.0% (4/8) and 25.0% (2/8) , respectively. The bleeding-related mortality rate was 50.0% (2/4) and 83.3% (5/6) , respectively. ②Of the 16 cases, 9 showed response to rF Ⅶ a treatment and the other 7 cases’bleeding signs did not alleviate. The median OS was 268.0 in 9 cases with response and 24.0 days in 7 cases without response, respectively. ③In patients with intestinal aGVHD complicated with intestinal hemorrhage, the median OS of observation group (n=6) and control group (n=15) were 25.5 days and 20.0 days, respectively. Conclusion Patients with hematological diseases, especially patients after allo-HSCT, had high bleeding-related mortality, and rFⅦa therapy had a obvious hemostatic efficacy. The survival rate of patients with response was higher than that of cases without response. The causes of poor hemostasis efficacy of rF Ⅶ a therapy were associated with unsatisfactory control of complications in patients with intestinal bleeding after allo-HSCT.

A multiple-stimuli-responsive drug-conjugated cross-linked micelles was prepared by radical copolymerization. The chemical structure, morphology, and size of the cross-linked micelles were characterized, and the drug loading of the micelle was calculated. The experimental results indicated that the hydrodynamic size of the drug-loaded micelles were about 100 nm, and the as prepared micelles could be degraded and swelled in presence of reducing glutathione (GSH). The low critical solution temperature (LCST) of the micelle was around 39.4℃. According to the experimental results, the micelles will shrink at temperature above the LCST. Subsequently, the accumulative drug release rate was up to 91.78% under acidic (pH 5.0), reductive (GSH 10 mmol/L) and high temperature (42.0℃) conditions mimicking the tumor microenvironment, while a relatively low release rate of 1.12% was observed without stimulation. The drug-conjugated cross-linked micelles showed a strong cell uptake behavior. In the cytotoxicity assay, the micelles exhibited effective anti-cancer activity and excellent biocompatibility. In brief, the experimental results show that the as-prepared drug-conjugated cross-linked micelle exhibits multiple stimuli-responsiveness, which holds great promise for anti-cancer drug delivery.

China ; Dissent and Disputes ; Humans ; Negotiating ; Physician-Patient Relations